Aethlon Medical Introduces HIV Treatment Technology; The HIV-Hemopurifier Documents Rapid Reduction of HIV Without the side-effects of Current Drug Treatments.

Health/Medical Writers

WASHINGTON, D.C.--(BW HealthWire)--Feb. 7, 2001

Aethlon Medical, Inc., (OTCBB:AEMD-news) based in San Diego, CA., announced today the introduction of its HIV-Hemopurifer technology at the Seventh Annual National Blood Product Safety Conference sponsored by the Cambridge Healthtech Institute.

"Our pre-clinical studies have documented the removal of 90% of HIV from human blood plasma during the equivalent of one overnight treatment," said Richard Tullis, Ph.D., Aethlon Vice President and presenter at the conference. "While we recognize that the HIV-Hemopurifier offers significant therapeutic potential for all patients, we feel our treatment technology will be especially important to patients who will now be waiting to initiate drug therapy as recommended under the new federal guidelines issued this week."

The HIV-Hemopurifier is a hollow-fiber dialysis cartridge that reduces viral load through the direct physical removal of the HIV in circulation. It is designed for use within an established infrastructure of dialysis machines located in hospitals and clinics worldwide. In addition to its therapeutic potential as a primary treatment prior to HIV drug initiation, the HIV-Hemopurifier has been targeted to be a conjunctive therapy to improve the performance of current drugs and is anticipated to be an important non-toxic treatment for patients who are unresponsive or resistant to established pharmaceutical regimens.

About Aethlon Medical

Aethlon Medical is a development stage, therapeutic device company engaged in the discovery and development of novel products that rapidly reduce the presence of viruses and other intoxicants in the blood. Aethlons' lead product candidate, the HIV-Hemopurifier(TM) is designed to fill the urgent need for new HIV/AIDS treatments that are effective in reducing viral load, have fewer side effects, and decrease the likelihood of treatment resistance. Other products in the Aethlon technology portfolio include Hemopurifiers that treat Lead Poisoning, Iron Overload, and curb the side effects of Chemotherapy.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. (the "Company"), or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers of this press release may obtain additional information on the Company in reports and other information filed in accordance with the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such reports and other information filed by the Company can be inspected and copied at the public reference facilities maintained by the Commission at the Public Reference Room, 450 Fifth Street, N.W., Washington, DC 20549. Copies of such material can also be obtained at prescribed rates from the Public Reference Section of the Commission, Washington, DC 20549 or by calling the Commission at 1-800-SEC-0330. In addition, Registration Statements and other filings made with the Commission through its Electronic Data Gathering Analysis and Retrieval System ("EDGAR") and publicly available through the Commission's website located at http://www.sec.gov.